Skin and soft tissue infections due to multiresistant Gram-positive microorganisms;Infecciones de piel y partes blandas por grampositivos multirresistentes

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 26, Issue SUPPL. 2, 2008, Pages 21-30

  Pigrau, Carlos ^a   Barberán, José ^b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL CENTRAL DE LA DEFENSA GÓMEZ ULLA   (Spain)

Author keywords

Cutaneous infections; Gram positive infections; MRSA; Skin and soft tissue infections

Indexed keywords

ANTIBIOTIC AGENT; AZTREONAM PLUS VANCOMYCIN; CEFTOBIPROLE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALBAVANCIN; DAPTOMYCIN; ERYTHROMYCIN; GENTAMICIN; LINEZOLID; METICILLIN; PENICILLIN G; RIFAMPICIN; TEICOPLANIN; TELAVANCIN; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN; VIRULENCE FACTOR;

ANEMIA; ANTIBIOTIC SENSITIVITY; CLINICAL FEATURE; DIARRHEA; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; REVIEW; SKIN INFECTION; SOFT TISSUE INFECTION; THROMBOCYTOPENIA;

EID: 46249128317     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1157/13123563     Document Type: Review

References (110)

1. Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK, Carey RB, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006; 355:666-74.
2. Zetola N, Francis JS, Nuermberger EL, Bishai WR. Community-acquired meticillin-resistant Staphylococcus aureus: an emerging threat. Lancet Infect Dis. 2005;5:275-86.
3. Harbarth S, Pittet D. Meticcillin-resistant Staphylococcus aureus. Clin Infect Dis. 2005;5:653-63.
4. King MD, Humphrey BJ, Wang YF, Kourbatova EV, Ray SM, Blumberg HM. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med. 2006;144:309-17.
5. Ito T, Ma XX, Takeuchi F, Okuma K, Yuzawa H, Hiramatsu K. Novel type V staphylococcal cassette chromosome mec driven by a novel cassette chromosome recombinase, ccrC. Antimicrob Agents Chemother. 2004;48:2637-51.
6. Fey PD, Said-Salim B, Rupp ME, Hinrichs SH, Boxrud DJ, Davis CC, et al. Comparative molecular analysis of community- or hospital-acquired methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2003;47:196-203.
7. Mongkolrattanothai K, Boyle S, Murphy TV, Daum RS. Novel non-mecA-containing staphylococcal chromosomal cassette composite island containing pbp4 and tagF genes in a commensal staphylococcal species: a possible reservoir for antibiotic resistance islands in Staphylococcus aureus. Antimicrob Agents Chemother. 2004;48:1823-36.
8. Staali L, Monteil H, Colin DA. The staphylococcal pore-forming leukotoxins open Ca2+ channels in the membrane of human polymorphonuclear neutrophils. J Membr Biol. 1998;162:209-16.
9. Laurent F, Lelievre H, Cornu M, Vandenesch F, Carret G, Etienne J, et al. Fitness and competitive growth advantage of new gentamicin-susceptible MRSA clones spreading in French hospitals. J Antimicrob Chemother. 2001;47:277-83.
10. Stankovic C, Majan PV. Healty children with invasive community-acquired methicillin-resistant Staphylococcus aureus infections. Pediatr Emerg Care. 2006;22:361-3.
11. Coronado F, Nicholas JA, Wallace BJ, Kohlerschmidt DJ, Musser K, Schoonmaker-Bopp, et al. Community-associated methicillin-resistant Staphylococcus aureus skin infections in a religious community. Epidemiol Infect. 2007;135:492-501.
12. Skiest D, Brown K, Hester J, Moore T, Crosby C, Mussa HR, et al. Community-onset methicillin-resistant Staphylococcus aureus in an urban HIV clinic. HIV Med. 2006;7:361-8.
13. Aiello AE, Lowy FD, Wright LN, Larson EL. Meticillin-resistant Staphylococcus aureus among US prisoners and military personnel: review and recommendations for future studies. Lancet Infect Dis. 2006;6:335-41.
14. Gilbert M, MacDonald J, Gregson D, Siushansian J, Zhang K, Elsayed S, et al. Outbreak in Alberta of community-acquired (USA300) methicillin-resistant Staphylococcus aureus in people with a history of drug use, homelessness or incarceration. CMAJ. 2006;175:149-54.
15. Romano R, Lu D, Holtom P. Outbreak of community-acquired methicillin-resistant Staphylococcus aureus skin infections among a collegiate football team. J Athl Train. 2006;41:141-5.
16. CDC. Community-associated meticillin-resistant Staphylococcus aureus infection among healthy newborns. MMWR. 2006;55:329-32.
17. CDC. Meticillin-resistant Staphylococcus aureus skin infections among tattoo reciepients: Ohio, Kentucky and Vermont, 2004-2005. MMWR. 2006;55:677-9.
18. CDC. Severe meticillin-resistant Staphylococcus aureus community-acquired pneumonia associate with inflenza: Louisiana and Georgia, December 2006- January 2007. MMWR. 2007;56:325-9.
19. Hidron AI, Kourbatova EV, Halvosa JS, Terrell BJ, McDougal LK, Tenover FC, et al. Risk factors for colonization with methicillin-resistant Staphylococcus aureus (MRSA) in patients admitted to an urban hospital: emergence of community-associated MRSA nasal carriage. Clin Infect Dis. 2005;41:159-66.
20. Salgado CD, Farr BM, Calfee DP. Community-acquired methicillin-resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors. Clin Infect Dis. 2003;36:131-9.
21. Broseta A, Chaves F, Rojo P, Otero JR. Emergence of a single clone of community-associated methicillin-resistant Staphylococcus aureus in southern Madrid children. Enferm Infecc Microbiol Clin. 2006;24:31-5.
22. Villegas ML, Cortes C, del Val B, Civille R, Alonsotarres C. Frecuencia de la leucocidina de Panton-Valentine en infecciones subcutáneas extrahospitalarias. XII Reunión de la SEIMC, Coruña 2007. Enferm Infecc Microbiol Clin. 2007. En prensa.
23. Espejo E, Boada N, Morera MA, SIMO M, Andres M, Pérez J, et al. Infecciones por Staphylococcus aureus resistente a la meticilina (SARM) de origen comunitario. XII Reunion de la SEIMC, Coruña 2007. Enferm Infecc Microbiol Clin. 2007. En prensa.
24. Seybold U, Kourbatova EV, Johnson JG, Halvosa SJ, Wang YF, King MD, et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections. Infect Dis. 2006;42:647-56.
25. Dinges MM, Orwin PM, Schlivert PM. Exotoxins of Staphylococcus aureus. Clin Microbiol Rev. 2000;13:16-34.
26. Bahrain M, Vasiliades M, Wolff M, Younus F. Five cases of bacterial endocarditis after furunculosis and the ongoing saga of community-acquired methicillin-resistant Staphylococcus aureus infections. Scand J Infect Dis. 2006;38:702-7.
27. Boussaud V, Parrot A, Mayaud C, Wislez M, Antoine M, Picard C, et al. Life-threatening hemoptysis in adults with community-acquired pneumonia due to Panton-Valentine leukocidin-secreting Staphylococcus aureus. Intensive Care Med. 2003;29:1840-3.
28. Pannaraj PS, Hulten KG, González BE, Mason EO Jr, Kaplan SL. Infective pyomyositis and myositis in children in the era of community-acquired, methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis. 2006;43:953-60.
29. Seybold U, Blumberg H. reading the leaves or decipherin DNA microarrays: are certain methicillin-resistant Staphylococcus aureus clones adapted to cause specific infections. Clin Infect Dis. 2007;44:502-5.
30. Miller LG, Quan C, Shay A, Mostafaie K, Bharadwa K, Tan N, et al. A prospective investigation of outcomes after hospital discharge for endemic, community-acquired methicillin-resistant and -susceptible Staphylococcus aureus skin infection. Clin Infect Dis. 2007;44:483-92.
31. Huang H, Flynn NM, King JH, Monchaud C, Morita M, Cohen SH. Comparisons of community-associated methicillin-resistant Staphylococcus aureus (MRSA) and hospital-associated MSRA infections in Sacramento, California. J Clin Microbiol. 2006;44:2423-7.
32. Tien I. Update on the management of skin, soft-tissue infections, and osteoarticular infections in children. Curr Opin Pediatr 2006; 18:254-9.
33. Grayson ML. The treatment triangle for Staphylococcal infections. N Engl J Med. 2006; 355:724-27.
34. Drew RH. Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections. Pharmacotherapy. 2007;27:227-49.
35. Barnes EV 2nd, Dooley DP, Hepburn MJ, Baum SE. Outcomes of community-acquired, methicillin-resistant Staphylococcus aureus, soft tissue infections treated with antibiotics other than vancomycin. Mil Med. 2006;171:504-7.
36. Szumowski JD, Cohen DE, Kanaya F, Mayer KH. Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinic. Antimicrob Agents Chemother. 2007;5:423-8.
37. Miller LG, Quan C, Shay A, Mostafaie K, Bharadwa K, Tan N, et al. A prospective investigation of outcomes after hospital discharge for endemic, community-acquired methicillin-resistant and -susceptible Staphylococcus aureus skin infection. Clin Infect Dis. 2007;44:483-92.
38. Pigrau C. Oxazolidinones and glycopeptides. Enferm Infecc Microbiol Clin. 2003;21:157-64.
39. Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C. Linezolid CSS-TI Study Group. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother. 2005;49:2260-6.
40. Howden BP, Charles PG, Johnson PD, Ward PB, Grayson ML. Improved outcomes with linezolid for methicillin-resistant Staphylococcus aureus infections: better drug or reduced vancomycin susceptibility? Antimicrob Agents Chemother. 2005;49:4816.
41. Kalil AC, Puumala S, Stoner J. Is linezolid superior to vancomycin for complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus? Antimicrob Agents Chemother. 2006;50:1910.
42. Weigelt J, Kaafarani HM, Itani KM, Swanson RN. Linezolid eradicates MRSA better than vancomycin from surgical-site infections. Am J Surg. 2004;188:760-6.
43. Plosker GL, Figgitt DP. Linezolid: a pharmacoeconomic review of its use in serious gram-positive infections. Pharmacoeconomics. 2005;23:945-64.
44. Lipsky BA, Itani K, Norden C, Linezolid Diabetic Foot Infections Study Group. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin- clavulanate. Clin Infect Dis. 2004;38:17-24.
45. Herruzo A, Pigrau C, Rodriguez D, Almiorante B, Villar M, Pahissa A, et al. Effectiveness and tolerability of prolonged linezolid therapy for chronic osteomyelitis. Corfu: 26th Annual Meeting European Bone and Joint Infection Society, septiembre de 2007.
46. Shorr AF, Kunkel MJ, Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J Antimicrob Chemother. 2005;56:923-9.
47. Lipopéptidos: una nueva clase de antibióticos para el tratamiento de las infecciones por microorganismos grampositivos. Monografía. Enferm Infecc Microbiol Clin 2006;5:1-71.
48. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI; Daptomycin 98-01 and 99-01 Investigators. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004;38:1673-81.
49. Lipsky BA, Stoutenburgh U. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. Antimicrob Chemother. 2005;55:240-5.
50. Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, et al. S. aureus Endocarditis and Bacteremia Study Group. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355:653-65.
51. Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E; Tigecycline 300 cSSSI Study Group; Tigecycline 305 cSSSI Study Group. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis. 2005;41 Suppl 5:S341-53.
52. Stryjewski ME, O'Riordan WD, Lau WK, Pien FD, Dunbar LM, Vallee M, et al; FAST Investigator Group. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis. 2005;40:1601-7.
53. Stryjewski ME, Chu VH, O'Riordan WD, Warren BL, Dunbar LM, Young DM, et al; FAST 2 Investigator Group. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother. 2006;50:862-7.
54. Jauregui LE, Babazadeh S, Seltzer E, Goldberg L, Krievins D, Frederick M, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis. 2005;41:1407-15.
55. Noel GJ, Strauss RS, Pypstra R; 00154 study group. Succesful treatment of complicated skin infections due to staphylococci, including methicillin resistant S. aureus (MRSA) with ceftobiprole. Abstract L1212. San Francisco: 46 ICAAC; 2006. p. 374.
56. Anaya DA, Dellinger EP. Necrotizing soft-tissue infection: diagnosis and management. Clin Infect Dis. 2007;44:705-10.
57. Jevons M. Celbernin-resistant staphylococci. BMJ. 1961;i:308-11.
58. EARSS annual report 2001. Bilthoven: European Antimicrobial Resistance Surveillance System (EARSS); 2002.
59. Fluit AC, Wielders CL, Verhoef J, Schmitz FJ. Epidemiology and susceptibility of 3,051 Staphylococcus aureus isolates from 25 university hospitals participating in the European SENTRY study. J Clin Microbiol. 2001;39:3727-32.
60. Diekema DJ, Pfaller MA, Schmitz FJ, Smayevsky J, Bell T, Jones RN, et al; SENTRY Participants Group. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRYAntimicrobial Surveillance Program, 1997-1999. Clin Infect Dis. 2001;32 Suppl 2:S114-32.
61. Cercenado E, Sanchez-Carrillo C, Alcala L, Bouza E. Current status of resistance of Staphylococcus in Spain. 4th National Study (1996). Work Group on the Study of Staphylococcus (in Spanish). Rev Clin Esp. 1997;197 Suppl 2:12-8.
62. Trallero EP, Arenzana JG, Castaneda AA, Grisolia LP. Unusual multiresistant Staphylococcus aureus in a newborn nursery. Am J Dis Child. 1981;135:689-92.
63. Cuevas O, Cercenado E, Vindel A, Guinea J, Sánchez-Conde M, Sánchez-Somolinos M, et al. Evolution of the antimicrobial resistance of Staphylococcus spp. In Spain: Five Nationwide Prevalence Studies, 1986 to 2002. Antimicrob Agents Chemother. 2004;48:4240-5.
64. Del Valle O, Trincado P, Martin MT, Gomez E, Cano A, Vindel A. The prevalence of methicillin-resistant Staphylococcus aureus phagotype 95 in the Hospitales Valld'Hebron of Barcelona (in Spanish). Enferm Infecc Microbiol Clin. 1999;17:498-505.
65. Graffunder EM, Venezia RA. Risk factors associated with nosocomial methicillin -resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. J Antimicrob Chemother. 2002;49:999-1005.
66. Safdar N, Maki DG. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, Enterococcus, gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med. 2002;136:834-44.
67. Cuevas O, Cercenado E, Bouza E, Castellares C, Trincado P, Cabrera R, et al. Molecular epidemiology of methicillin-resistant Staphylococcus aureus in Spain: a multicentre prevalence study (2002). Clin Microbiol Infect. 2007;13:250-6.
68. Jones ME, Schmitz FJ, Fluit AC, Acar J, Gupta R, Verhoef J, and the SENTRY participants group. Frequency of occurrence and antimicrobial susceptibility of bacterial pathogens associated with skin and soft tissue infections during 1997 from an international surveillance programme. Eur J Clin Microbiol Infect Dis. 1999;18:403-8.
69. Swartz MN. Cellulitis. N Engl J Med. 2004;350:904-12.
70. DiNubile MJ, Lipsky BA. Complicated infections of skin and skin structures: when the infection is more than skin deep. J Antimicrob Chemother. 2004;53 Suppl 2:ii37-ii50.
71. Vinh DC, Embil JM. Rapidly progressive soft tissue infections. Lancet Infect Dis. 2005;5:501-13.
72. Graffunder EM, Venezia RA. Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. J Antimicrob Chemother. 2002;49:999-1005.
73. Eady EA, Cove JH. Staphylococcal resistance revisited: community- adquired methicillin resistant Staphylococcus aureus, an emerging problem for the management of skin and soft tissue infections. Curr Opin Infect Dis. 2003;16:103-24.
74. Eron LJ, Lipsky BA, Low DE, Nathwani D, Tice AD, Volturo GA. Managing skin and soft tissue infections: expert panel recommendations on key decision points. J Antimicrob Chemother. 2003;52 Suppl 1: i13-i7.
75. Moise-Broder PA, Sakoulas G, Eliopoulos GM, Schentag JJ, Forrest A, Moellering RC Jr. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis. 2004;38:1700-5.
76. Stryjewski ME, Chu VH, O'Riordan WD, Warren BL, Dunbar LM, Young DM, et al; FAST 2 Investigator Group. Telavancin versus standard therapy for treatment of complicated skin and soft tissue infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother. 2006;50:862-7.
77. Kirst HA, Thompson DG, Nicas TI. Historical yearly usage of vancomycin. Antimicrob Agents Chemother. 1998;42:1303-4.
78. Mohr JF, Murray BE. Point: vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2007;44:1536-42.
79. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother. 1997;40:135-6.
80. Sieradzki K, Roberts RB, Haber SW, Tomasz A. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med. 1999;340:517-23.
81. Fridkin SK. Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know. Clin Infect Dis. 2001;32:108-15.
82. Tenover FC, Biddle JW, Lancaster MV. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis. 2001;7:327-32.
83. Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S, et al. Disemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet. 1997;350:1670-3.
84. Liu C, Chambers HF. Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob Agents Chemother. 2003;47: 3040-5.
85. Ariza J, Pujol M, Cabo J, Peña C, Fernández N, Liñares J, et al. Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. Lancet. 1999;353:1587-8.
86. Sievert DM, Boulton ML, Stolman G, Johnson D, Stobiersky MG, Downes FP, et al. Staphylococcus aureus resistant to vancomycin: United States, 2002. MMWR Morb Mortal Wkly Rep. 2002;51:565-7.
87. Chang S, Sievert DM, Hageman JC, Boulton ML, Tenover FC, Downes FP, et al; Vancomycin-Resistant Staphylococcus aureus Investigative Team. Infection with vancomycinresistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med. 2003;348:1342-7.
88. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol. 2004;42:2398-402.
89. Moise-Broder PA, Sakoulas G, Eliopoulos GM, Schentag JJ, Forrest A, Moellering RC Jr. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis. 2004;38:1700-5.
90. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. Highdose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med. 2006;166:2138-44.
91. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; seventeenth informational supplement. Standard M100-S17. Wayne: Clinical and Laboratory Standards Institute; 2007.
92. Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006;42:S35-9.
93. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet. 2004;43:925-42.
94. Jeffres MN, Isakow W, Doherty JA, McKinnon PS, Ritchie DJ, Micek ST, et al. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest. 2006; 130:947-55.
95. European Committee on Antimicrobial Susceptibility Testing. Antimicrobial wild type distributions of microorganisms [accedido 1 Mar 2007]. Disponible en: http: //217.70.33.99/Eucast2/
96. Del Mar Fernandez de Gatta Garcia M, Revilla N, Calvo MV, Dominquez-Gil A, Sanchez Navarro A. Pharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients. Intensive Care Med. 2006; 33:279-85.
97. US Food and Drug Administration, Anti-Infective Drugs Advisory Committee. Briefing information: Cubist Pharmaceuticals, Inc. Cubicin (daptomycin for injection) briefing material. 6 March 2006 [accedido 30 Abr 2007]. Disponible en: http://www.fda.gov/cder/foi/nda/2003/21-572_Cubicin.htm.
98. Jeffres MN, Micek ST, Isakow W, et al. Increased incidence of nephrotoxicity with higher vancomycin serum trough concentrations [abstract K-789]. In: Program and abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington: American Society for Microbiology; 2006. p. 327.
99. Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med. 1992;117:390-8.
100. Stevens DL, Bisno AL, Chambers HF, Everett ED, Dellinger P, Goldstein EJC, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis. 2005;41:1373-406.
101. Gemmell CG, Edwards DI, Fraise AP, Gould FK, Ridgway GL, Warren RE. Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J Antimicrob Chemother. 2006;57:589-608.
102. Documento de consenso sobre el tratamiento antimicrobiano de las infecciones en el pie del diabético. Rev Esp Quimioterap. 2007;20:77-92.
103. Faoagali JL, Thong ML, Grant D. Ten years' experience with methicillin-resistant Staphylococcus aureus in a large Australian hospital. J Hosp Infect. 1993;20:113-9.
104. Wilson DH. Clindamycin in the treatment of soft tissue infections: a review of 15 019 patients. Br J Surg. 1980;67:93-6.
105. Schumer W, Nicols RL, Miller B, Samet ET, McDonald GO. Clindamycin in the treatment of soft-tissue infections. Arch Surg. 1973;106:578-81.
106. Le Frock JL, Prince RA, Klainer AS, et al. Parenteral clindamycin in the treatment of aerobic, anaerobic and mixed aerobic-anaerobic infections. Curr Ther Res. 1977;212:289-314.
107. Klemper MS, Styrt B. Prevention of recurrent staphylococcal skin infections with low-dose oral clindamycin therapy. JAMA. 1988;260:2682-5.
108. Guía de tratamiento de las infecciones de piel y tejidos blandos. Rev Esp Quimioterap. 2006;19:378-94.
109. Stevens DL, Laine BM, Mitten JE. Comparision of single and combination antimicrobial agents for prevention of experimental gas gangrene caused by Clostridium perfringens. Antimicrob Agents Chemother. 1987;31: 312-6.
110. Stevens DL, Madera-Kelly K, Richards D. In vitro antimicrobial effects of various combinations of penicillin and clindamycin against four strains of Streptococcus pyogenes. Antimicrob Agents Chemother. 1998; 42:1266-8.